NCT06727669 Longitudinal Cohort of Thrombosis and Hemostasis Diseases
| NCT ID | NCT06727669 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University People's Hospital |
| Condition | Immune Thrombocytopenia |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2024-11-01 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2024-11-01 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multicenter, prospective, longitudinal, observational cohort study to investigate thrombosis and hemostasis diseases in Chinese patients. This study will collect basic information, diagnostic and treatment information, as well as medical expense information of patients from medical records.The incidence and risk factors of thrombosis and hemostasis diseases, the treatment methods, prognosis and medical expenses of these patients in China will be analyzed. The study will use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.
Eligibility Criteria
Inclusion Criteria: * Patients who were diagnosed as thrombosis and hemostasis diseases. Exclusion Criteria: * Long-term follow-up information for patients is not available for any reason, such as not being available or having a serious concomitant disease. * Patients with alcohol and drug addictions or mental illness affect their ability to comply with study requirements. * According to the investigator, there are conditions that may endanger the patient's safety or affect his/her compliance.
Contact & Investigator
Xiao-Hui Zhang, MD
PRINCIPAL INVESTIGATOR
Peking University Institute of Hematology, Peking University People's Hospital
Frequently Asked Questions
Who can join the NCT06727669 clinical trial?
This trial is open to participants of all sexes, studying Immune Thrombocytopenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06727669 currently recruiting?
Yes, NCT06727669 is actively recruiting participants. Contact the research team at fuhaixia_210@163.com for enrollment information.
Where is the NCT06727669 trial being conducted?
This trial is being conducted at Beijing, China, Beijing, China, Beijing, China, Zhengzhou, China and 1 additional location.
Who is sponsoring the NCT06727669 clinical trial?
NCT06727669 is sponsored by Peking University People's Hospital. The principal investigator is Xiao-Hui Zhang, MD at Peking University Institute of Hematology, Peking University People's Hospital. The trial plans to enroll 3,000 participants.